Brief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
Today 02:35
BRIEF-HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis Oct 23 (Reuters) - Hbm Holdings Ltd 2142.HK:
NMPA APPROVES BATOCLIMAB INJECTION FOR GENERALIZED MYASTHENIA GRAVIS
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study